The Cancer Research UK (CRUK) Barts Centre aims to transform the lives of those with and at risk of cancer through innovative basic, translational, clinical and population-based research into various cancer types. We are committed to not only making our research cutting-edge but importantly both relevant and accessible. To achieve this, we believe in an active partnership between the researchers and the patient, carers and the public.
Our PPI research advisory group brings together researchers from within the CRUK Barts Centre with PPI advocates who have an interest in cancer research. Our PPI advocates provide invaluable contributions by bringing alternative perspectives and ideas to those of the academic researchers, to improve different aspects of the research that we conduct here at the CRUK Barts Centre. The input of our PPI research advisory group ensures that our research is designed and delivered with the patients in mind, and provides a vehicle to raise further awareness of the importance of research.
Daniel is an Investment Manager at Seraphim Capital making venture investments in the space/aerospace ecosystem, and formerly a venture investor at a materials/bio fund. He has a PhD in Chemistry from the University of Bristol, specialising in Nanomaterials, and a Bachelor of Applied Science and Engineering from the University of Toronto.
Daniel has experience of evaluating cancer treatments as a venture investor, and experience of the Canadian cancer treatment system as a family member of those being treated.
Many of Daniel’s immediate and extended family have lost their lives to cancer. Daniel would like to do his part to help progress cancer treatment and to make the patient experience better.
Rachel Cunningham is an arts events and marketing specialist, running a small consultancy, ‘Project Spotter,’ from her home in East Sussex. She was diagnosed with Non-Hodgkin lymphoma in November 2017, after a nurse found an abnormal lump in her spleen while she was having an ultrasound scan. Rachel undertook 7 months of chemotherapy, and was found to have a complete metabolic response. She is currently under ‘watch and wait’ care with Eastbourne District Hospital.
Rachel wanted to use her cancer experience for something positive, and felt that her communication skills and knowledge in the field of marketing could prove useful in the role.
After developing breast cancer in April 2008 and going through the treatment, Clare wanted to know more about the disease, the research and treatments available.
Clare took part in a trial at the time and since then has been very interested in cancer research. Friends and family of Clare have developed different types of cancer over the last few years, which has increased her interest in this area.
Although Clare’s treatment was over 10 years ago, she is still interested in the treatment of cancer as more and more people seem to be developing the disease.
Celia is a Registered Nurse, with experience in caring for patients with cancer at all levels of the disease, from diagnosis, through to treatment and palliative care. Celia was diagnosed with breast cancer in October 2015, for which she received surgery, chemotherapy and radiotherapy.
The experience made Celia realise the importance of research, particularly into cancers of unmet need such a triple negative breast cancer, to enable more targeted cancer treatments with a view to eliminating the often disabling side effects.
Celia believes it is essential that patients understand the importance of research to enable the advancement of cancer treatment, and feels that she is in the ideal position to help to bridge the gap between research and the practicalities that patients are encountering on a daily basis when they have been given a cancer diagnosis.